| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6182879 | Gynecologic Oncology | 2014 | 10 Pages |
Abstract
Advances in systemic therapy for vulvar SCC are urgently needed, especially in the setting of recurrent and metastatic disease. A focus on the investigation of new targeted agents is encouraged and consideration of quality of life and sexual health issues is essential. International cooperation and adaptive trial designs are required to improve outcomes for this group of traditionally under-served women.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Clare J. Reade, Lua R. Eiriksson, Helen Mackay,